Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Tislelizumab in pMMR/MSS LARC
NCT04989855Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in rectal cancer, sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04989855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989855.